Maria del Carmen Sandi PerezACADEMIC POSITION:
Professor, Director of the Laboratory of Behavioral Genetics, Brain Mind Institute, Ecole Polytechnique Federale de Lausanne (EPFL), Switzerland.
EDUCATION:
BS MS Salamanca, Spain, 1984
PhD Cajal Institute, CSIC, and University Autonoma of Madrid, Spain, 1988
PROFESSIONAL EXPERIENCE:
Postdoc at INSERM, Bordeaux, France, and Cajal Institute Madrid, Spain, 1989-1990
Postdoc at the Open University, UK, 1991-1992, 1996
Research Associate, Cajal Institute, CSIC, Madrid, 1993-1995
Associate Professor Tenured, UNED University, Madrid, 1996-2003
Sabbatical Professor, University of Bern, Switzerland, 2002-2003
Assistant Professor Tenure-Track, EPFL, 2003-2007
Associate Professor Tenured, EPFL, 2007-2012
Full Professor, EPFL, 2012-
Director, Brain Mind Institute, EPFL, 2012-
PRINCIPAL BOARDS:
President, European Brain and Behavior Society (EBBS), 2009-2012
Editor-in-Chief Frontiers in Behavioral Neuroscience
Member of Scientific Advisory Panel, European College Neuropsychopharmacology (ECNP)
Member of the European Dana Alliance for the Brain (EDAB)
Associate Editor Frontiers in Neuroscience
Editorial Board Member Neurobiology of Learning and Memory
Editorial Board Member Journal of Psychiatry Research
Editorial Board Member Stress
Editorial Board Member Biology of Mood and Anxiety Disorders
Editorial Board Member Neuroscience and Biobehavioral Reviews
Didier TronoAfter obtaining an M.D. from the University of Geneva and completing a clinical training in pathology, internal medicine and infectious diseases in Geneva and at Massachusetts General Hospital in Boston, Didier Trono embarked in a scientific career at the Whitehead Institute for Biomedical Research of MIT. In 1990, he joined the faculty of the Salk Institute for Biological Studies to launch a center for AIDS research. He moved back to Europe seven years later, before taking the reins of the newly created EPFL School of Life Sciences, which he directed from 2004 to 2012. He is now actively engaged in the efforts of Switzerland to integrate new technologies in the fields of precision medicine and personalized health.
Gerardo TurcattiSenior scientific level (R&D) with extensive experience in the management of multidisciplinary technological projects. Prof. Gerardo Turcatti, directs the academic technological platform, Biomolecular Screening Facility (BSF) at the EPFL he created in 2006. In the framework of the NCCR-Chemical Biology, he is project leader of the program ACCESS (An Academic Chemical Screening Platform for Switzerland). Previously he co-founded and acted as CTO of Manteia S.A., a Swiss-based company that developed high throughput DNA sequencing technologies currently owned by Illumina and used in the ‘Next Generation Sequencing’ instruments. Prior to this experience, Prof. Turcatti had a long multidisciplinary career in R&D divisions of Biotechnology and Pharmaceutical companies with extensive expertise in several Chemical Biology-related disciplines such as Drug Screening, Chemical Biology, Bio-analytical Chemistry, DNA and Protein Chemistry. Prof. Turcatti earned his Master in Chemical Engineering at the University of Geneva and his PhD in Chemistry and Biochemistry from the EPFL where he received the award for the best doctoral thesis of the year.
Stewart ColeProfessor Stewart Cole is an international authority in bacterial molecular-genetics and genomics. He has made outstanding contributions in several fields including: bacterial anaerobic electron transport; genome analysis of retroviruses and papillomaviruses; antibiotic resistance mechanisms; and the molecular microbiology of toxigenic clostridia. His studies on isoniazid and multidrug resistance in Mycobacterium tuberculosis, together with his pioneering work on the pathogenicity, evolution and genomics of the tubercle and leprosy bacilli, have made him an undisputed leader in the field of mycobacterial research. The findings of his research are of direct relevance to public health and disease-control in both the developing world and the industrialised nations. He has published over 250 scientific papers and review articles, and holds many patents.
